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Abstract: A high nuclear grade is crucial to predicting tumor recurrence and metastasis in clear
cell renal cell carcinomas (ccRCCs). We aimed to compare the mRNA profiles of tumor tissues
and preoperative plasma in patients with localized T1 stage ccRCCs, and to evaluate the potential
of the plasma mRNA profile for predicting high-grade ccRCCs. Data from a prospective cohort
(n = 140) were collected between November 2018 and November 2019. Frozen tumor tissues and
plasma were used to measure PBRM1, BAP1, SET domain-containing 2 (SETD2), KDM5C, FOXC2,
CLIP4, AQP1, DDX11, BAIAP2L1, and TMEM38B mRNA levels, and correlation with the Fuhrman
grade was investigated. Multivariate logistic regression analysis revealed significant association
between high-grade ccRCC and SETD2 and DDX11 mRNA levels in tissues (odds ratio (β) = 0.021,
95% confidence interval (CI): 0.001–0.466, p = 0.014; β = 6.116, 95% CI: 1.729–21.631, p = 0.005,
respectively) and plasma (β = 0.028, 95% CI 0.007–0.119, p < 0.001; β = 1.496, 95% CI: 1.187–1.885,
p = 0.001, respectively). High-grade ccRCC prediction models revealed areas under the curve of
0.997 and 0.971 and diagnostic accuracies of 97.86% and 92.86% for the frozen tissue and plasma,
respectively. SETD2 and DDX11 mRNA can serve as non-invasive plasma biomarkers for predicting
high-grade ccRCCs. Studies with long follow-ups are needed to validate the prognostic value of these
biomarkers in ccRCCs.
Keywords: biomarker; clear cell renal cell carcinoma; high-grade; plasma; mRNA profile
1. Introduction
Renal cell carcinoma (RCC) is the sixth and tenth most common cancer in men and women
worldwide, respectively [1]. The rates of incidence of RCC have increased, owing to the increased
efficiency of detection using abdominal imaging [2]. Although incidental masses detected in images
are small and localized, up to 17% of patients with RCC present with distant metastases at the time
of diagnosis, and one-third of patients relapse after surgery [3,4]. Numerous studies have focused
on the identification of molecular biomarkers for the prognosis of small RCCs or pT1 RCCs (tumors
≤ 7 cm). Among the various treatment options available to clinicians, ranging from surgical resection
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to non-surgical approaches, biomarkers are essential for the therapeutic management of RCC; however,
an accurate and reliable prognostic indicator remains to be definitively identified [5,6].
Mutations of several tumor suppressor genes (polybromo 1 (PBRM1), BRCA1-associated 1 (BAP1),
and SET domain-containing 2 (SETD2)) are associated with clear cell RCC (ccRCC) tumorigenesis [7].
PBRM1 and BAP1 mutations are largely mutually exclusive, where mutations of BAP1 mutations
are significantly associated with high-grade, high-stage tumors that result in low survival [8].
Furthermore, mutations of lysine-specific demethylase 5C (KDM5C) are associated with poor oncological
outcomes [9]. Our previous studies have demonstrated that forkhead box protein C2 (FOXC2) and
cytoskeleton-associated, protein-glycine (CAP-Gly)-rich, domain-containing linker protein family
member 4 (CLIP4) mutations were associated with early-stage ccRCC, and a synchronous metastasis [10]
and validation study confirmed that PBRM1, BAP1, and FOXC2 were shown to be significantly
associated with aggressive early-stage ccRCC through target sequencing and immunohistochemistry [5].
In our latest study, we have identified new candidate genes (AQP1, DDX11, BAIAP2L1, and TMEM38B)
by RNA sequencing of formalin-fixed, paraffin-embedded tissues and validating in frozen tissues [11].
Conventional needle biopsies are invasive and subject to procedural complications. Up to one
in six biopsies have been reported to be associated with a definite risk [12], and renal mass biopsy
(RMB) has shown a relatively high histologic concordance rate, but low nuclear grade concordance
rate [13–15]. A blood-based test, also known as a liquid biopsy, offers a potential alternative to
invasive techniques [16]. In particular, liquid biopsies for circulating tumor cells or circulating tumor
DNA (ctDNA) derived from the cell-free DNA (cfDNA) of tumor cells represent a promising method;
however, few studies have focused on cfDNA or ctDNA analysis for RCC [17,18]. Considering
the lack of satisfactory blood-based markers for ccRCC, there is an urgent need to identify new
biomarkers [6,17,18]. Moreover, currently, there exist no panels for cfDNA or ctDNA profiling, and it
is comparatively expensive and time-consuming, thus limiting the widespread clinical application of
liquid biopsies.
To help resolve these issues, this study aims to evaluate the potential of plasma mRNA profiles
in predicting high-grade pT1N0M0 ccRCCs. We compared the mRNA profiles of tumor tissues and
plasma samples from patients to determine a correlation between mRNA levels and high nuclear grade
(Fuhrman grades 3 and 4), one of the most important factors for predicting tumor recurrence and
metastasis after surgery [6]. For the selection of genes, we used the most renown genes that have been
identified and validated in our studies and other studies by several research teams. No other studies
have been performed on investigating the expression levels of identified genes in plasma. We expect
that plasma mRNA profiling could become an inexpensive approach applicable for clinical practice.
2. Results
2.1. Baseline Characteristics
The clinicopathologic features of patients are listed in Table 1. The mean tumor size was 3.0± 1.5 cm.
The patient group was primarily comprised of Fuhrman grade 2 (45.0%) and 3 (41.4%) tumors.
Table 1. Clinical and histopathological characteristics.
Characteristic Clinicopathological Data (n = 140)
Sex male/female 97/43 (69.3/30.7%)
Age (years) 56.0 ± 12.3
Mean tumor diameter (cm) 3.0 ± 1.5






Data are presented as mean ± standard deviation or median (interquartile range) for continuous variables, and as a
percentage for categorical variables.
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2.2. Expression of Target Genes in Frozen Tissue and Plasma
Using univariate analysis, we observed that the relative mRNA levels of SETD2, AQP1, and DDX11
in the frozen tissue significantly correlated with high-grade ccRCC (Figure 1a, Figure 2, and Table
S1). Univariate logistic regression analysis revealed that SETD2, AQP1, and DDX11 levels were
significantly associated with high-grade ccRCC (Table 2). Among these three genes, we only included
those that were significantly associated in the plasma samples, in order to effectively compare the
performance of prediction models, including the same variables for both frozen tissue and plasma
samples. Multivariate logistic regression analyses revealed that SETD2 and DDX11 were significantly
associated with high-grade ccRCC for the frozen tissues and plasma samples (Table 2).
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Table 2. Univariate and multivariate logistic regression analyses of the mRNA levels of target genes
associated with high-grade clear cell renal cell carcinoma.
High-Grade ccRCC Univariate β (95% CI) p a Multivariate β (95% CI) p b
FOXC2 0.998 (0.982–1.014) 0.792
CLIP4 0.997 (0.988–1.007) 0.548
PBRM1 0.987 (0.961–1.013) 0.321
SETD2 0.303 (0.177–0.520) <0.001 0.021 (0.001–0.466) 0.014
BAP1 1.620 (0.488–5.383) 0.431
KDM5C 0.984 (0.876–1.107) 0.794
AQP1 0.012 (0.002–0.077) <0.001
DDX11 2.625 (1.811–3.805) <0.001 6.116 (1.729–21.631) 0.005
BAIAP2L1 1.039 (0.942–1.146) 0.446
TMEM38B 0.993 (0.959–1.029) 0.700
FOXC2 0.995 (0.967–1.024) 0.736
CLIP4 1.006 (0.993–1.019) 0.367
PBRM1 0.939 (0.800–1.102) 0.440
SETD2 0.045 (0.015–0.132) <0.001 0.028 (0.007–0.119) <0.001
BAP1 0.926 (0.818–1.048) 0.225
KDM5C 1.013 (0.989–1.037) 0.289
AQP1 1.008 (0.988–1.028) 0.451
DDX11 1.504 (1.255–1.803) <0.001 1.496 (1.187–1.885) 0.001
BAIAP2L1 1.010 (0.988–1.033) 0.384
TMEM38B 0.986 (0.972–1.001) 0.062
a p-value calculated using logistic regression for univariate analysis; b p-value calculated using logistic regression
for multivariate analysis.
2.3. Correlation between mRNA Levels in the Frozen Tissue and Plasma
SETD2 mRNA levels in the frozen tissue positively correlated with its plasma levels (Pearson’s
correlation coefficient (r) = 0.512, p < 0.001). Similar results were obtained for DDX11 (r = 0.896,
p < 0.001).
2.4. SETD2 and DDX11 Levels in Frozen Tissue and Plasma, in Accordance with the Fuhrman Grade
The levels of SETD2 mRNA in the plasma decreased with an increase in the Fuhrman grade,
displaying statistically significant differences between grades (Figure 1b and Table S2). However,
the levels of SETD2 mRNA in the frozen tissue did not adhere to overall trends of decrease in SETD2
mRNA levels as Fuhrman grade increased, only showing statistical differences between grades 2 and 3
and grades 2 and 4. In contrast, DDX11 levels increased with an increase in the Fuhrman grade of the
frozen tissue and plasma samples. Moreover, excluding grades 1 and 2, the difference in the levels was
significant among all other grades (Table S2). We further verified the expressions of SETD2 and DDX11
from The Cancer Genome Atlas (TCGA) ccRCC database using UALCAN (Figure S1). The TCGA
database showed similar expressions trend, according to Fuhrman grades, for both SETD2 and DDX11.
SETD2 expression levels in normal kidney tissue were higher than those in ccRCC; in addition, those in
ccRCCs decreased as the Fuhrman grades increased, while DDX11 levels were the lowest at normal
kidney tissue and increased as the Fuhrman grades increased.
2.5. Prediction Model Comparison
Prediction models based on the mRNA levels of SETD2 and DDX11 in frozen tissue presented
an area under the curve (AUC) of 0.997 and an accuracy of 97.86%; similarly, those based on plasma
mRNA levels of these markers presented an AUC and accuracy of 0.971 and 92.86%, respectively
(Table 3 and Figure 3). Although both prediction models performed well, those based on mRNA levels
in the frozen tissue were significantly better (p = 0.031). As an independent factor, DDX11 in the frozen
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tissue gave a better prediction model than SETD2 in frozen tissue, while SETD2 in plasma gave a better
prediction model than DDX11 in plasma.
Table 3. Performance comparison of logistic regression models for prediction of high-grade clear cell
renal cell carcinoma.
Included Variables in Models Sensitivity Specificity PPV NPV Accuracy (%) AUC (95% CI)
SETD2 (frozen tissue) 0.84 0.59 0.84 0.59 71.43% 0.779 (0.704–0.853)
DDX11 (frozen tissue) 1.00 0.93 1.00 0.93 96.43% 0.964 (0.931–0.997)
SETD2 + DDX11 (frozen tissue) 0.97 0.99 0.97 0.99 97.86% 0.997 (0.992–1.000)
SETD2 (plasma) 0.86 1.00 1.00 0.86 92.86% 0.952 (0.918–0.987)
DDX11 (plasma) 0.84 0.70 0.84 0.70 77.14% 0.836 (0.771–0.900)
SETD2 + DDX11 (plasma) 0.93 0.93 0.93 0.93 92.86% 0.971 (0.947–0.994)
PPV: positive predictive value; NPV: negative predictive value; AUC: area under the curve; CI: confidence interval.
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Cancers 2020, 12, 1182 8 of 13
concerns associated with its high non-diagnostic rate and complications, including biopsy tract seeding;
however, recent studies have reported improved safety and diagnostic accuracy of RMB in detecting
malignant tumors and histological subtyping [14,15,19]. Nevertheless, RMB continues to have poor
accuracy for assessing the Fuhrman grade, a key determinant of the biological potential of ccRCC,
as well as the disease stage that is used in multiple prognostic models; moreover, nuclear grade
heterogeneity is a substantial issue in RMB [19]. We believe that the use of RMB in conjunction with
plasma mRNA levels of SETD2 and DDX11 can improve the accuracy of assessing the Fuhrman grade.
Further studies are needed to confirm the predictive ability of the combination of mRNA levels in
plasma and tissues in RMB samples.
DDX11 is an important gene for predicting tumor aggressiveness based on the Fuhrman grade.
Bhattacharya et al. [20] had reported that DDX11 inhibition decreased the rate of proliferation
and induced apoptosis in melanoma cells. Moreover, DDX11 was significantly upregulated and
associated with a poor prognosis in patients with lung adenocarcinoma [21]. Consistent with these
findings, we observed that DDX11 expression increased with the Fuhrman grade in frozen tissue and
plasma samples.
Furthermore, SETD2 was significantly associated with high-grade ccRCC in frozen tissues and
plasma, and SETD2 levels decreased with an increase in the Fuhrman grade. SETD2, which encodes
a histone methyltransferase, is a novel tumor suppressor gene in ccRCC. The Cancer Genome Atlas
(TCGA) revealed that alterations in DNA methylation correlate with SETD2 mutations [22]. SETD2
mutations have been reported at rates of 11.6% and 7.4% in TCGA and Memorial Sloan-Kettering
Cancer Center cohorts, respectively [23], and Liu et al. [24] reported a rate of deficiency of SETD2
of 34.1% in a multicenter study. SETD2 mutation has been found to be associated with adverse
oncological outcomes in our previous study and other multicenter studies, thereby suggesting a
general role of SETD2 in disease progression [5,24]. Consistent with our findings, lower SETD2 mRNA
levels have been reported in breast cancer tissues, thereby linking decreased SETD2 mRNA levels to
tumorigenesis [25].
AQP1 was reported to be an important gene associated with high-grade ccRCC in frozen tissues,
although no significance has been reported for its plasma levels. Huang et al. [26] demonstrated that
AQP1 levels were significantly higher in patients whose tumors were smaller, of lower grade, or either
a lower stage or lacking microvascular invasion. Furthermore, higher AQP1 levels were associated
with a better prognosis of cancer-specific and cancer-free survival. In accordance with these findings,
we found similar trends for AQP1 expression, wherein AQP1 expression levels were higher in patients
with low-grade ccRCC.
However, this study has a few limitations. First, the study period was only one year. Therefore,
the follow-up period was too short to evaluate the significance of biomarkers with respect to ccRCC
prognostic factors, such as recurrence, cancer-specific death, or survival. Furthermore, none of the 140
patients included in this study developed recurrence, metastasis, or cancer-specific death. As a high
nuclear grade is currently the most important prognostic factor for predicting tumor recurrence and
metastasis after surgery [6], we evaluated the correlation between the expression of biomarkers and a
high nuclear grade. Second, due to the uneven number of patients in each Fuhrman grade, statistical
significances were not noted between some grade groups, and expression levels between some grade
groups did not adhere to overall mRNA expression trends of low- and high-grade ccRCC. Recently,
the World Health Organization/International Society of Urological Pathology (WHO/ISUP) grading
has been replacing Fuhrman grading, which previously had been used widely, since the Fuhrman
grading requires simultaneous assessment of three different parameters, resulting in poor interobserver
reproducibility [27]. In our institution, the nuclear grade was classified according to both the Fuhrman
and the ISUP grading systems, and our analysis on ISUP grading results were similar (Tables S3 and S4).
Moreover, since our study referred to the previous studies that analyzed the genetic profiles according
to Fuhrman grading, we tried to adhere to Fuhrman grading in this study. In a future study, we are
planning to match the number of patients in each grade group by using ISUP grading, which is more
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widely used. Third, the intratumoral heterogeneity of primary tumors is a substantial problem, even in
small renal masses [28]. Intratumoral heterogeneity is known to cause sampling bias in conventional
sampling methods, such as needle biopsies, leading to false-negative results or suboptimal therapy
selection, due to low grading accuracy [13–15]. Liquid biopsies can supplement this limitation, and
our findings highlight plasma SETD2 and DDX11 mRNA levels as promising candidates for predicting
high-grade ccRCC with this approach. Although the relative quantification approach was used in this
study, the absolute quantification approach would provide more exact values, which is helpful in real
clinical practices. Therefore, the use of absolute quantification of plasma SETD2 and DDX11 levels
should be investigated in a future study. Moreover, by including the analysis of the normal kidney
tissue and healthy donor plasma, a future study could suggest the use of the expressions of SETD2
and DDX11 as the tool for diagnosis of early ccRCCs. Furthermore, the discrepancy between the
different validity of SETD2 and DDX11—which is that DDX11 in frozen tissue gives a better prediction
model than SETD2, while the opposite results occur for SETD2 in plasma—was reported in our study.
Although we do not clearly understand the underlying mechanisms, the distortion of biomarkers by
different release processes in tissue and plasma could be explained by the inclusion of the normal
kidney tissue and healthy donor plasma. Therefore, in our coming projects, we have included the
analysis of normal kidney tissue and healthy donor plasma, which will be reported in a future study.
We are currently conducting clinical trials for investigating the use of ctDNA as a marker in
urological malignancies (ClinicalTrials.gov identifier: NCT04197414). We believe that this study will
serve as the cornerstone for the initiation of the liquid biopsy era in the context of ccRCC diagnosis
and management.
4. Materials and Methods
4.1. Patients and Tissues
A prospective cohort (ClinicalTrials.gov identifier: NCT03694912) was selected between November
2018 and November 2019; it included patients with pT1N0M0 ccRCC (≤7 cm). All subjects gave their
informed consent for inclusion before they participated in the study. The study was approved by the
Institutional Review Board of the Yonsei University Health System (approval no: 4-2018-0753).
In total, 140 patients with ccRCC (≤7 cm), who were treated via nephrectomy alone and for
whom frozen tumor tissue and matched preoperative plasma were available, were included in
the study. Patients not presenting typical characteristics of ccRCC, those receiving neoadjuvant or
adjuvant systemic therapy, those with a history of inherited von Hippel–Lindau disease, or those with
synchronous/metachronous bilateral RCC were excluded. Patients with no or very little tumor tissue
(less than 5% of the area occupied by invasive cancer cells), insufficient RNA, or inadequate RNA
quality were also excluded.
Clinicopathologic data, including age, sex, body mass index, and tumor size were recorded
for each patient. The histological subtype was assessed in accordance with the 2016 World Health
Organization Renal Neoplasms guidelines [29], and invasion (perinephric/sinus fat or microscopic
vascular invasion), and lymph node involvement were evaluated in accordance with the guidelines of
the 2010 American Joint Committee on Cancer [30]. Grading was based on Fuhrman grading [31] and
the WHO/ISUP grading system [32]. Low-grade ccRCC consists of Fuhrman or WHO/ISUP grades I
and II, whereas grades III and IV constitute high-grade ccRCC. Diameters of the primary tumors were
obtained via imaging.
We analyzed the expression of six genes (PBRM1, BAP1, SETD2, KDM5C, FOXC2, and CLIP4)
reportedly associated with ccRCC, and four genes (AQP1, DDX11, BAIAP2L1, and TMEM38B) from
our previous RNA-seq analysis of aggressive ccRCC at the clinical T1 stage [11].
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4.2. Processing of Blood Samples
Peripheral blood was collected from each participant, aliquoted into ethylenediaminetetraacetic
acid-containing tubes, and centrifuged at 1600× g for 10 min at 4 ◦C. Plasma was carefully transferred
to fresh tubes and further centrifuged at 4000× g for 10 min at 4 ◦C. Plasma samples were then stored
at −80 ◦C until further analyses.
4.3. RNA Extraction and Reverse Transcription-Quantitative Polymerase Chain Reaction (RT-qPCR)
Total RNA was extracted from frozen tissue and plasma samples using TRIzol (Ambion,
Life Technologies, Carlsbad, CA, USA). In general, RNA isolated from 1 mL of plasma was dissolved in
20 µL of diethyl-pyrocarbonate (DEPC)-treated water. The quantity and quality of RNA was assessed
using a Nanodrop spectrophotometer (NanoDrop ND-1000, Thermo Scientific, Wilmington, DE, USA).
One microgram of each sample was reverse-transcribed into first-strand cDNA using the iNtRon
Maxime RT PreMix (iNtRON catalog no. 25082), in accordance with the manufacturer’s protocol. Then
qPCR was performed using the Power SYBR Green Master Mix (Thermo Fisher, catalog no. A25742,
Waltham, MA, USA) in a 10 µL reaction volume comprised of 5 µL of SYBR Green master PCR mix,
1 µL of forward and reverse primer (10 pmol), 1 µL of diluted cDNA template, and sterile distilled
water. Conditions for amplification were as follows: initial denaturation at 95 ◦C for 10 min, 40 cycles
of denaturation at 95 ◦C for 15 s, annealing at 58 ◦C for 60 s, elongation at 72 ◦C for 60 s, and final
elongation at 72 ◦C for 5 min. qPCR was performed on the ABI StepOnePlus Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA). All quantifications were carried out using GAPDH as a
reference gene to normalize relative target gene expression levels. GAPDH levels were constant across
samples, with no significant variations in either the frozen tissues or the plasma, respectively, although
GAPDH levels were different between them. The PCR primer sequences are presented in Table S5.
Relative gene expression was analyzed using the 2−∆∆CT method. The transcript copy number of
each genes was normalized to the GAPDH transcript copy number for each sample. RT-qPCR was
performed in triplicates or more, and the results were analyzed in an investigator-blinded manner.
4.4. UALCAN Analysis
UALCAN [33], an online tool used to analyze gene expression data from The Cancer Genome
Atlas (TCGA) database (including 72 normal kidney tissues and 533 primary tumors), was used to
validate the mRNA expressions of SETD2 and DDX11 according to Fuhrman grades. A p-value less
than 0.05 was considered to indicate a statistically significant difference [34].
4.5. Statistical Analyses
Data have been presented as the mean ± standard deviation or median (interquartile range) for
continuous variables, and as a percentage for categorical variables. For univariate analysis, t-test and
univariate logistic regression analysis were used to compare continuous variables. Multivariate logistic
regression analyses were performed for factors that were significantly associated with high-grade
ccRCCs in both frozen tissue and plasma in univariate logistic regression analyses. Correlation
between the mRNA levels of SETD2 and DDX11 in frozen tissue and plasma were determined using
Pearson’s correlation analysis. Levels of SETD2 and DDX11 mRNA, in accordance with the Fuhrman
or WHO/ISUP grade, were analyzed using one-way analysis of variance, followed by the Bonferroni
post-hoc test. SPSS software version 23.0 (IBM Corp., Armonk, NY, USA) was used for all statistical
analyses. All statistical tests were two-tailed, and a p-value less than 0.05 was considered significant.
GraphPad Prism software (version 8.0, GraphPad Software, Inc., La Jolla, CA, USA) was used for
generating the graphs.
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4.6. Prediction Model Comparison
The accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value
(NPV) of the prediction models were calculated. The receiver operating characteristic curves and area
under the curve (AUC) were used to examine and compare the performance of the prediction models
for high-grade ccRCC using the R package (R Development Core Team, 2010).
5. Conclusions
In summary, we evaluated the mRNA profiles of candidate genes in the frozen tissues and plasma
of patients with localized T1N0M0 ccRCC. SETD2 and DDX11 mRNA levels in frozen tissues and
plasma were significantly associated with high-grade ccRCC. The determination of plasma SETD2 and
DDX11 mRNA levels in the plasma can be used as a means of supplementing the low-grade accuracy of
conventional RMB, by including ease, safety, and the ability to provide more information on the tumor.
Moreover, non-invasive plasma biomarkers can complement RMB in the clinical characterization of
localized T1 renal masses.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/5/1182/s1,
Table S1: mRNA levels of target genes in low-grade vs. high-grade clear cell renal cell carcinoma. Table S2:
SETD2 and DDX11 levels in clear cell renal cell carcinomas of different Fuhrman grades. Table S3: Univariate and
multivariate logistic regression analyses of the mRNA levels of target genes associated with high-grade clear cell
renal cell carcinoma (by International Society of Urological Pathology (ISUP) grading system). Table S4: SETD2
and DDX11 levels in clear cell renal cell carcinomas of different ISUP grades. Table S5: PCR primer sequences.
Figure S1: Validation of the expression of SETD2 and DDX11 in the TCGA database, according to Fuhrman grades.
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validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer
Res Treat. 2016, 160, 439–446. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
